Wellington Hospital
12
3
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
17%
2 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
Role: collaborator
PeRiOperative Medicine Platform Trial
Role: collaborator
Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Role: collaborator
Shock Energy for Electrical Cardioversion of Persistent Atrial Fibrillation
Role: lead
NA-AION Risk Factors: New Perspectives
Role: collaborator
Measurements of Angulation of the C-spine
Role: collaborator
Neural, Behavioural, and Clinical Effects of tDCS in PDOC; Feasibility Study
Role: collaborator
Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele
Role: collaborator
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
Role: collaborator
Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)
Role: collaborator
Role of Cardiac CT in Rapid Access Chest Pain Clinics (RADICAL)
Role: collaborator
Comparison of Glue With Sutures for Pterygium Surgery
Role: lead
All 12 trials loaded